Indian drugmakers see U.S. sales hit by delay in new approvals

MUMBAI (Reuters) - Indian drugmakers expect a slowdown in new generic drug approvals by the U.S. Food and Drug Administration (FDA) to weigh on sales in their largest market for at least two more quarters, due to an ongoing overhaul of the review process.

via Reuters: Health News Read More Here..